Last Price$91.71.4%
Market Cap$18.6B
P/EBITDA LTM
20.2x
5Y avg
11.5x
Medical - Instruments & Supplies industry
median
(0.1x)
Stock quality & Intrinsic value
6/10
0.0% undervalued
The Cooper Companies, Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Oct'05 | Oct'06 | Oct'07 | Oct'08 | Oct'09 | Oct'10 | Oct'11 | Oct'12 | Oct'13 | Oct'14 | Oct'15 | Oct'16 | Oct'17 | Oct'18 | Oct'19 | Oct'20 | Oct'21 | Oct'22 | Oct'23 | Oct'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 4.0x | 1.6x | 3.2x | 1.0x | 1.5x | 2.6x | 3.1x | 3.3x | 4.2x | 4.8x | 5.4x | 4.4x | 5.3x | 4.9x | 4.4x | 6.2x | 5.6x | 15.0x | 17.8x | 20.2x |
Overvalued or undervalued?
Check the intrinsic value for COO
and see if it's the right time to invest.
The Cooper Companies, Inc. (COO) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
The Cooper Companies, Inc.COO
18.4x
8.4%
32.2%
10.1%
Median Peer Set
19.9x
1.7%
15.9%
10.4%
Repligen CorporationRGEN
102.9x
(21.1%)
(80.9%)
5.6%
Intuitive Surgical, Inc.ISRG
75.1x
17.2%
27.7%
27.8%
Alcon Inc.ALC
22.9x
8.5%
182.9%
10.3%
West Pharmaceutical Services, Inc.WST
22.9x
(1.9%)
(15.5%)
17.0%
ResMed Inc.RMD
20.9x
10.9%
13.4%
21.8%
Baxter International Inc.BAX
18.8x
(69.5%)
(100.0%)
(6.9%)
Becton, Dickinson and CompanyBDX
18.0x
4.2%
18.3%
8.4%
AptarGroup, Inc.ATR
12.9x
2.7%
30.2%
10.5%
Hologic, Inc.HOLX
12.0x
(0.0%)
81.1%
19.6%
Masimo CorporationMASI
(51.4x)
0.6%
(42.5%)
4.0%
COO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Oct'05 | Oct'06 | Oct'07 | Oct'08 | Oct'09 | Oct'10 | Oct'11 | Oct'12 | Oct'13 | Oct'14 | Oct'15 | Oct'16 | Oct'17 | Oct'18 | Oct'19 | Oct'20 | Oct'21 | Oct'22 | Oct'23 | Oct'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 806.6 64.6% | 859.0 6.5% | 950.6 10.7% | 1,063.2 11.8% | 1,080.4 1.6% | 1,158.5 7.2% | 1,330.8 14.9% | 1,445.1 8.6% | 1,587.7 9.9% | 1,717.8 8.2% | 1,797.1 4.6% | 1,966.8 9.4% | 2,139.0 8.8% | 2,532.8 18.4% | 2,653.4 4.8% | 2,430.9 (8.4%) | 2,922.5 20.2% | 3,308.4 13.2% | 3,593.2 8.6% | 3,895.4 8.4% |
| Cost of Goods Sold (COGS) | 309.8 | 333.0 | 431.1 | 453.1 | 483.9 | 481.8 | 526.0 | 521.1 | 560.9 | 626.2 | 726.8 | 793.7 | 773.2 | 900.5 | 896.6 | 896.1 | 966.7 | 1,168.8 | 1,235.3 | 1,299.7 |
% margin | 496.8 61.6% | 526.0 61.2% | 519.5 54.7% | 610.0 57.4% | 596.5 55.2% | 676.7 58.4% | 804.8 60.5% | 924.0 63.9% | 1,026.8 64.7% | 1,091.6 63.5% | 1,070.3 59.6% | 1,173.1 59.6% | 1,365.8 63.9% | 1,632.3 64.4% | 1,756.8 66.2% | 1,534.8 63.1% | 1,955.8 66.9% | 2,139.6 64.7% | 2,357.9 65.6% | 2,595.7 66.6% |
| Operating Expenses | 352.5 | 406.7 | 464.0 | 481.5 | 442.8 | 486.4 | 577.2 | 635.6 | 685.7 | 785.1 | 833.6 | 849.0 | 936.7 | 1,204.8 | 1,229.1 | 1,223.0 | 1,450.0 | 1,632.0 | 1,824.8 | 1,890.0 |
| Research & Development Expenses (R&D) | 42.9 | 34.5 | 39.9 | 35.5 | 33.3 | 35.3 | 43.6 | 51.7 | 58.8 | 66.3 | 69.6 | 65.4 | 69.2 | 84.8 | 86.7 | 93.3 | 92.7 | 110.3 | 137.4 | 155.1 |
| Selling, General & Administrative Expenses (SG&A) | 298.0 | 357.8 | 408.0 | 429.3 | 391.6 | 433.1 | 513.1 | 559.9 | 596.7 | 683.1 | 712.5 | 722.8 | 799.1 | 973.3 | 996.6 | 992.5 | 1,211.2 | 1,342.2 | 1,501.2 | 1,533.7 |
% margin | 135.8 16.8% | 112.9 13.1% | 45.9 4.8% | 127.0 11.9% | 149.9 13.9% | 189.9 16.4% | 227.6 17.1% | 283.4 19.6% | 305.9 19.3% | 306.5 17.8% | 236.7 13.2% | 324.1 16.5% | 429.1 20.1% | 403.1 15.9% | 546.7 20.6% | 311.8 12.8% | 505.8 17.3% | 507.6 15.3% | 533.1 14.8% | 705.7 18.1% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 43.6 | 58.7 | 67.5 | 53.8 | 44.1 | 36.7 | 17.3 | 11.8 | 9.2 | 8.0 | 18.1 | 26.2 | 33.4 | 82.7 | 68.0 | 36.8 | 23.1 | 57.3 | 105.3 | 114.3 |
| Pre-tax Income | 108.5 | 73.3 | 0.7 | 76.2 | 114.8 | 124.4 | 192.8 | 275.5 | 312.3 | 296.5 | 215.5 | 295.6 | 394.0 | 331.9 | 477.4 | 266.5 | 491.5 | 475.3 | 412.9 | 582.3 |
% effective tax rate | 16.7 15.4% | 7.1 9.7% | 11.9 1,765.5% | 10.7 14.1% | 14.3 12.4% | 11.6 9.3% | 17.3 9.0% | 26.8 9.7% | 15.4 4.9% | 24.7 8.3% | 10.3 4.8% | 20.7 7.0% | 21.1 5.4% | 192.0 57.8% | 10.7 2.2% | 28.1 10.5% | (2,453.2) (499.1%) | 89.5 18.8% | 118.7 28.7% | 190.0 32.6% |
% margin | 91.7 11.4% | 66.2 7.7% | (11.2) (1.2%) | 65.5 6.2% | 100.5 9.3% | 112.8 9.7% | 175.4 13.2% | 248.3 17.2% | 296.2 18.7% | 269.9 15.7% | 203.5 11.3% | 273.9 13.9% | 372.9 17.4% | 139.9 5.5% | 466.7 17.6% | 238.4 9.8% | 2,944.7 100.8% | 385.8 11.7% | 294.2 8.2% | 392.3 10.1% |
| EPS | 2.06 | 1.49 | (0.25) | 1.46 | 2.23 | 2.48 | 3.74 | 5.18 | 6.09 | 5.61 | 4.20 | 5.65 | 7.63 | 2.85 | 2.36 | 1.21 | 14.96 | 1.96 | 1.49 | 1.97 |
| Diluted EPS | 2.04 | 1.44 | (0.25) | 1.43 | 2.21 | 2.43 | 3.63 | 5.05 | 5.96 | 5.51 | 4.14 | 5.59 | 7.52 | 2.81 | 2.33 | 1.20 | 14.78 | 1.94 | 1.48 | 1.96 |
% margin | 133.0 16.5% | 168.2 19.6% | 127.0 13.4% | 206.3 19.4% | 238.6 22.1% | 244.9 21.1% | 305.4 22.9% | 398.4 27.6% | 446.8 28.1% | 442.7 25.8% | 425.0 23.6% | 520.1 26.4% | 613.6 28.7% | 689.7 27.2% | 826.2 31.1% | 622.9 25.6% | 863.7 29.6% | 908.6 27.5% | 885.9 24.7% | 705.7 18.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is The Cooper Companies, Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 20.2x, based on the financial report for Oct 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for The Cooper Companies, Inc. have been 13.9x over the past three years, and 12.1x over the past five years.
2) Is The Cooper Companies, Inc.'s P/EBITDA LTM Good?
As of today, The Cooper Companies, Inc.'s P/EBITDA LTM is 20.2x, which is higher than industry median of (0.1x). It indicates that The Cooper Companies, Inc.'s P/EBITDA LTM is Bad.